Effect of Statins on a Wide Range of Health Outcomes: a Cohort Study Validated by Comparison with Randomized Trials

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2008 Nov 14

PMID 19006546

Citations 104

Authors

Liam Smeeth

Ian Douglas

Andrew J Hall

Richard Hubbard

Stephen Evans

Affiliations

Soon will be listed here.

Abstract

Aims: To assess the effect of statins on a range of health outcomes.

Methods: We undertook a population-based cohort study to assess the effect of statins on a range of health outcomes using a propensity score-based method to control for differences between people prescribed and not prescribed statins. We validated our design by comparing our results for vascular outcomes with the effects established in large randomized trials. The study was based on the United Kingdom Health Improvement Network database that includes the computerized medical records of over four and a half million patients.

Results: People who initiated treatment with a statin (n = 129,288) were compared with a matched sample of 600,241 people who did not initiate treatment, with a median follow-up period of 4.4 years. Statin use was not associated with an effect on a wide range of outcomes, including infections, fractures, venous thromboembolism, gastrointestinal haemorrhage, or on specific eye, neurological or autoimmune diseases. A protective effect against dementia was observed (hazard ratio 0.80, 99% confidence interval 0.68, 0.95). There was no effect on the risk of cancer even after > or =8 years of follow-up. The effect sizes for statins on vascular end-points and mortality were comparable to those observed in large randomized trials, suggesting bias and confounding had been well controlled for.

Conclusions: We found little evidence to support wide-ranging effects of statins on health outcomes beyond their established beneficial effect on vascular disease.

Citing Articles

The role of statins in dementia or Alzheimer's disease incidence: a systematic review and meta-analysis of cohort studies.

Du Y, Yu Z, Li C, Zhang Y, Xu B Front Pharmacol. 2025; 16:1473796.

PMID: 39963242 PMC: 11830700. DOI: 10.3389/fphar.2025.1473796.

Genetic correlation between genes targeted by lipid-lowering drugs and venous thromboembolism: A drug-target Mendelian randomization study.

Li M, Duan H, Luo J, Tan Y, Liu M, Zhao X Medicine (Baltimore). 2024; 103(51):e40770.

PMID: 39705479 PMC: 11666180. DOI: 10.1097/MD.0000000000040770.

Statins for the primary prevention of venous thromboembolism.

Wang Z, Zhang P, Tian J, Zhang P, Yang K, Li L Cochrane Database Syst Rev. 2024; 11:CD014769.

PMID: 39498835 PMC: 11536507. DOI: 10.1002/14651858.CD014769.pub2.

Risk of Venous Thromboembolism in Statin Users Compared to Fibrate Users in the United Kingdom Clinical Practice Research Datalink (UK CPRD) GOLD.

Ayodele O, Cabral H, McManus D, Jick S Clin Epidemiol. 2024; 16:683-697.

PMID: 39386131 PMC: 11463176. DOI: 10.2147/CLEP.S481448.

Cognitive function in dyslipidemia patients: exploring the impact of statins.

Wang W, Li X Front Neurol. 2024; 15:1436010.

PMID: 39350969 PMC: 11439768. DOI: 10.3389/fneur.2024.1436010.

References

Poynter J, Gruber S, Higgins P, Almog R, Bonner J, Rennert H . Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352(21):2184-92. DOI: 10.1056/NEJMoa043792. View

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

Singh S, Loke Y . Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports. Drug Saf. 2006; 29(12):1123-32. DOI: 10.2165/00002018-200629120-00004. View

Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

Meier C, Schlienger R, Kraenzlin M, Schlegel B, Jick H . HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000; 283(24):3205-10. DOI: 10.1001/jama.283.24.3205. View

Selnes O, Vinters H . Vascular cognitive impairment. Nat Clin Pract Neurol. 2006; 2(10):538-47. DOI: 10.1038/ncpneuro0294. View

Glynn R, Schneeweiss S, Wang P, Levin R, Avorn J . Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006; 59(8):819-28. DOI: 10.1016/j.jclinepi.2005.12.012. View

Shepherd J, Blauw G, Murphy M, Bollen E, Buckley B, Cobbe S . Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360(9346):1623-30. DOI: 10.1016/s0140-6736(02)11600-x. View

Ralph Edwards I, Star K, Kiuru A . Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 2007; 30(6):515-25. DOI: 10.2165/00002018-200730060-00005. View

10.

Hall N, Gale C, Syddall H, Phillips D, Martyn C . Risk of macular degeneration in users of statins: cross sectional study. BMJ. 2001; 323(7309):375-6. PMC: 37398. DOI: 10.1136/bmj.323.7309.375. View

11.

Brookhart M, Patrick A, Dormuth C, Avorn J, Shrank W, Cadarette S . Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007; 166(3):348-54. DOI: 10.1093/aje/kwm070. View

12.

Abeles A, Pillinger M . Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?. Arthritis Rheum. 2006; 54(2):393-407. DOI: 10.1002/art.21521. View

13.

Zandi P, Sparks D, Khachaturian A, Tschanz J, Norton M, Steinberg M . Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005; 62(2):217-24. DOI: 10.1001/archpsyc.62.2.217. View

14.

Robbins M, Iqbal A, Hershman R . Lovastatin-induced hemolytic anemia: not a class-specific reaction. Am J Med. 1995; 99(3):328-9. DOI: 10.1016/s0002-9343(99)80170-3. View

15.

Li G, Larson E, Sonnen J, Shofer J, Petrie E, Schantz A . Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007; 69(9):878-85. DOI: 10.1212/01.wnl.0000277657.95487.1c. View

16.

Fedson D . Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006; 43(2):199-205. PMC: 7107836. DOI: 10.1086/505116. View

17.

Rockwood K, Kirkland S, Hogan D, MacKnight C, Merry H, Verreault R . Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002; 59(2):223-7. DOI: 10.1001/archneur.59.2.223. View

18.

Lewis J, Schinnar R, Bilker W, Wang X, Strom B . Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2006; 16(4):393-401. DOI: 10.1002/pds.1335. View

19.

Sundram F, Roberts P, Kennedy B, Pavord S . Thrombotic thrombocytopenic purpura associated with statin treatment. Postgrad Med J. 2004; 80(947):551-2. PMC: 1743097. DOI: 10.1136/pgmj.2003.017178. View

20.

Sturmer T, Joshi M, Glynn R, Avorn J, Rothman K, Schneeweiss S . A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006; 59(5):437-47. PMC: 1448214. DOI: 10.1016/j.jclinepi.2005.07.004. View